Combination therapy of tacrolimus and intravenous cyclophosphamide for remission induction of lupus nephritis
- Conditions
- lupus nephritis
- Registration Number
- JPRN-UMIN000004893
- Lead Sponsor
- Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Not provided
Patients are excluded if they meet any one of the following criteria. 1)Patients whose serum creatinine is 2 mg/dL or more; or creatinine clearance is 30 mL/min/1.73m2 or less. 2)Patients needing steroid pulse therapy. 3)Patients having received intravenous cyclophosphamide or steroid pulse therapy within 6 months of the start of the study. 4)Patients having suffered from hypersensitivity against the ingredients of tacrolimus capsules. 5)Patients administered with cyclosporine or bosentan. 6)Patients administered with potassium sparing diuretics. 7)Patients pregnant or suspected to be pregnant; or breast-feeding; or expecting to be pregnant during the study period. 8)Patients administered with pentostatin. 9)Patients having suffered from hypersensitivity against the ingredients of injectable cyclophosphamide. 10)Patients having a serious infectious disease. 11)Patients considered ineligible by a doctor in charge for other reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete remission rate at 6 months after the start of protocol treatment
- Secondary Outcome Measures
Name Time Method